Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Capital Expenditures (2020 - 2023)

Historic Capital Expenditures for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $47000.0.

  • Candel Therapeutics' Capital Expenditures fell 8297.1% to $47000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $457000.0, marking a year-over-year decrease of 6476.48%. This contributed to the annual value of $16000.0 for FY2024, which is 9649.89% down from last year.
  • Per Candel Therapeutics' latest filing, its Capital Expenditures stood at $47000.0 for Q4 2023, which was down 8297.1% from $103000.0 recorded in Q3 2023.
  • Candel Therapeutics' Capital Expenditures' 5-year high stood at $1.8 million during Q1 2021, with a 5-year trough of -$281000.0 in Q3 2021.
  • Its 4-year average for Capital Expenditures is $340571.4, with a median of $245500.0 in 2022.
  • Per our database at Business Quant, Candel Therapeutics' Capital Expenditures plummeted by 13870.52% in 2021 and then skyrocketed by 26176.47% in 2022.
  • Candel Therapeutics' Capital Expenditures (Quarter) stood at $453000.0 in 2020, then rose by 11.26% to $504000.0 in 2021, then crashed by 45.24% to $276000.0 in 2022, then tumbled by 82.97% to $47000.0 in 2023.
  • Its last three reported values are $47000.0 in Q4 2023, $103000.0 for Q3 2023, and $169000.0 during Q2 2023.